EUCAST technical note on voriconazole and Aspergillus spp

Clin Microbiol Infect. 2013 Jun;19(6):E278-80. doi: 10.1111/1469-0691.12148. Epub 2013 Feb 15.

Abstract

The European Committee on Antimicrobial Susceptibility Testing Subcommittee on Antifungal Susceptibility Testing (EUCAST-AFST) has determined breakpoints for voriconazole against Aspergillus spp. This Technical Note is based on the EUCAST rationale document for voriconazole (available on the EUCAST website: http://www.eucast.org). Voriconazole breakpoints are based on epidemiological cut-off values, pharmacokinetic/pharmacodynamic data and clinical experience. Breakpoints will be reviewed regularly or when new data emerge.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antifungal Agents / pharmacology*
  • Antifungal Agents / therapeutic use
  • Aspergillosis / drug therapy
  • Aspergillosis / epidemiology
  • Aspergillus / drug effects*
  • Humans
  • Microbial Sensitivity Tests* / standards
  • Pyrimidines / pharmacology*
  • Pyrimidines / therapeutic use
  • Triazoles / pharmacology*
  • Triazoles / therapeutic use
  • Voriconazole

Substances

  • Antifungal Agents
  • Pyrimidines
  • Triazoles
  • Voriconazole